Aprea Therapeutics Inc. (APRE)
NASDAQ: APREHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
APRE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.03M
- EPS (TTM)
- -$0.95
- Dividend yield
- None
- 52-week range
- 0.548 – 1.69
- Day range
- 0.55 – 0.608
- Volume / Avg
- 235.47K / 277.08K
- Beta
- —
- Shares outstanding
- 12.59M
52-week range
APRE stock today
Aprea Therapeutics (APRE) closed at $0.5582 on Oct 8, down 7.74% (-$0.0468), versus the S&P 500's 0.47% decline. At this level, APRE sits near the bottom of its 52-week range of $0.548 to $1.69: 67.0% below the high and 1.9% above the low. Aprea Therapeutics has posted a net loss over the last twelve months (EPS of -$0.95), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aprea Therapeutics
Company profileAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Oren Gilad Ph.D.
- Headquarters
- Doylestown, PA
- Employees
- 8
- IPO year
- 2019
- Website
- aprea.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$3.73+568.22%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Aprea Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BOLTBolt Biotherapeutics Inc. | 3.65 | +1.39% | $7.03M | vs APRE |
| ACXPAcurx Pharmaceuticals Inc. | 1.25 | -3.85% | $6.95M | vs APRE |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs APRE |
| ENVBEnveric Biosciences Inc. | 1.52 | +1.67% | $6.80M | vs APRE |
| NRSNNeuroSense Therapeutics Ltd. | 3.58 | -6.28% | $6.79M | vs APRE |
| LEXXLexaria Bioscience Corp. | 3.20 | -8.57% | $6.74M | vs APRE |
| TRAWTraws Pharma Inc. | 0.4803 | +0.27% | $7.38M | vs APRE |
| SKYESkye Bioscience Inc. | 1.68 | +1.82% | $7.44M | vs APRE |
Indexes, lists and sector
Appears in lists
Aprea Therapeutics stock FAQ
What is Aprea Therapeutics's stock price today?
APRE last traded at $0.5582 as of Oct 8, 4:00 PM EDT, down 7.74% on the day. Prices are delayed at least 15 minutes.
Who is Aprea Therapeutics's CEO?
Dr. Oren Gilad Ph.D. is the chief executive officer of Aprea Therapeutics Inc., which has about 8 employees.
What is the APRE 52-week high?
The 52-week high for APRE is $1.69 and the 52-week low is $0.548. The stock is currently 67.0% below its high.